Dx&Vx Establishes Strategic Collaborations with Top Global Firms at BIO USA 2026
At the BIO International Convention 2026, held from June 22 to June 25 in San Diego, Dx&Vx (DXVX, KOSDAQ: 180400) showcased its expanding global partnering initiatives, cutting through the crowded biotech landscape with a clear focus on out-licensing opportunities. The event saw participation from over 20,000 industry professionals, positioning itself as the largest biotechnology business forum in the world.
During this influential convention, Dx&Vx met with more than 40 pharmaceutical and biotechnology companies from around the globe. The main agenda revolved around establishing potential overseas out-licensing deals, marking the company’s aggressive push towards global collaboration. Kevin Kwon, the CEO of Dx&Vx, emphasized the strong interest generated by their innovative pipelines, including promising candidate drugs aimed at treating cancer and obesity.
One of the standout moments was a 13-minute corporate presentation delivered by Kwon, where he outlined the company’s key therapeutic candidates. This included OVM-200, an anti-cancer drug that has garnered widespread attention following successful Phase 1 results, presented by their UK partner, Oxford VacMedix, at the recent American Society of Clinical Oncology (ASCO) Annual Meeting earlier in May.
Moreover, the highlights did not end there, as Dx&Vx introduced their oral obesity drug candidate, touted as the world's first irreversible GLP-1 receptor agonist. This unique mechanism of action has drawn considerable interest due to its promising efficacy, leading to a series of follow-up meetings with potential partners. Such innovations are critical in a market where obesity therapies are considerably needed.
With talks gaining traction, Kwon stated, "The outcomes of our meetings with a plethora of key players in the pharmaceutical sector are indeed promising. As we navigate through these discussions, our focus remains on successfully securing out-licensing agreements and enhancing our global presence."
The strategic collaborations initiated at BIO USA reflect not just a commitment to innovation but also a robust approach to leveraging synergies with larger, established firms that can help accelerate the development and commercial viability of their unique therapies. The expanding portfolio from Dx&Vx underscores one of the key trends in the biotech industry: the necessity for companies to forge partnerships that can amplify their research capabilities and market reach.
At the heart of discussions was a strong interest in the nucleic acid/LNP stabilization platform (KRNA) and two additional pipelines from their subsidiary, Avixgen, which are focused on treating dry eye disease and enhancing drug delivery across the blood-brain barrier. The convergence of innovative therapies being showcased by Dx&Vx was indicative of the transformative potential they hold in addressing some of the most pressing health concerns globally.
As the world continues to grapple with health challenges posed by cancer and obesity, events like BIO USA not only foster collaboration but also invigorate the biotechnology landscape, presenting opportunities for small firms like Dx&Vx to make significant strides in their mission. The future looks promising for Dx&Vx as they continue their pursuit of strategic alliances that stand to elevate their products onto the world stage.
During this influential convention, Dx&Vx met with more than 40 pharmaceutical and biotechnology companies from around the globe. The main agenda revolved around establishing potential overseas out-licensing deals, marking the company’s aggressive push towards global collaboration. Kevin Kwon, the CEO of Dx&Vx, emphasized the strong interest generated by their innovative pipelines, including promising candidate drugs aimed at treating cancer and obesity.
One of the standout moments was a 13-minute corporate presentation delivered by Kwon, where he outlined the company’s key therapeutic candidates. This included OVM-200, an anti-cancer drug that has garnered widespread attention following successful Phase 1 results, presented by their UK partner, Oxford VacMedix, at the recent American Society of Clinical Oncology (ASCO) Annual Meeting earlier in May.
Moreover, the highlights did not end there, as Dx&Vx introduced their oral obesity drug candidate, touted as the world's first irreversible GLP-1 receptor agonist. This unique mechanism of action has drawn considerable interest due to its promising efficacy, leading to a series of follow-up meetings with potential partners. Such innovations are critical in a market where obesity therapies are considerably needed.
With talks gaining traction, Kwon stated, "The outcomes of our meetings with a plethora of key players in the pharmaceutical sector are indeed promising. As we navigate through these discussions, our focus remains on successfully securing out-licensing agreements and enhancing our global presence."
The strategic collaborations initiated at BIO USA reflect not just a commitment to innovation but also a robust approach to leveraging synergies with larger, established firms that can help accelerate the development and commercial viability of their unique therapies. The expanding portfolio from Dx&Vx underscores one of the key trends in the biotech industry: the necessity for companies to forge partnerships that can amplify their research capabilities and market reach.
At the heart of discussions was a strong interest in the nucleic acid/LNP stabilization platform (KRNA) and two additional pipelines from their subsidiary, Avixgen, which are focused on treating dry eye disease and enhancing drug delivery across the blood-brain barrier. The convergence of innovative therapies being showcased by Dx&Vx was indicative of the transformative potential they hold in addressing some of the most pressing health concerns globally.
As the world continues to grapple with health challenges posed by cancer and obesity, events like BIO USA not only foster collaboration but also invigorate the biotechnology landscape, presenting opportunities for small firms like Dx&Vx to make significant strides in their mission. The future looks promising for Dx&Vx as they continue their pursuit of strategic alliances that stand to elevate their products onto the world stage.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.